Home/ Stocks/ AVTX

Avalo Therapeutics, Inc. Common Stock

AVTX XNAS

$18.32 -0.31 (-1.66%) ▼ 15-min delayed

Open

$18.87

High

$19.05

Low

$17.90

Volume

730.2K

Market Cap

$1.00B

About Avalo Therapeutics, Inc. Common Stock

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 33 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-19,630,000	$-0.98
FY 2025	$59.0K	$-78,259,000	$-5.84
Q3 2025	$0	$-30,625,000	$-2.19
Q2 2025	$0	$-20,765,000	$-1.92

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for AVTX yet. Check out our latest market news or earnings calendar.

Get AVTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Avalo Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.